Bradykinin
From PeptidePlaza, the free peptide reference · Entry #1012 · Recovery · Sources fetched 2026-09-10 · Editorial standards
Bradykinin (also known as L-Bradykinin, Kallidin I, Callidin I, Kallidin-9) is a recovery research peptide. Bradykinin is an endogenous human peptide involved in various physiological processes, including blood coagulation and inflammation.
Bradykinin, also known as Kallidin I, is an endogenous human peptide composed of nine amino acid residues. It plays a role in the kinin-kallikrein system, where kininogens act as inhibitors of thiol proteases. High molecular weight (HMW)-kininogen is important in blood coagulation by facilitating the optimal positioning of prekallikrein and factor XI next to factor XII, and it inhibits thrombin- and plasmin-induced platelet aggregation. Low molecular weight (LMW)-kininogen also inhibits platelet aggregation but is not involved in blood clotting. Bradykinin is currently investigational and has been extensively studied, with research focusing on its role in angioedema, sepsis, and atherosclerotic cardiovascular disease.
1 Mechanism of action
Kininogens are inhibitors of thiol proteases. HMW-kininogen plays an important role in blood coagulation by helping to position optimally prekallikrein and factor XI next to factor XII; HMW-kininogen inhibits the thrombin- and plasmin-induced aggregation of thrombocytes. LMW-kininogen inhibits the aggregation of thrombocytes. LMW-kininogen is in contrast to HMW-kininogen not involved in blood clotting
2 Chemical and physical properties
| CAS number | 58-82-2 |
|---|---|
| Molar mass | 1060.2 g/mol |
| Purity (typical) | Not independently verified |
| Storage | −20 °C, lyophilised powder, desiccated |
| Solubility | Sterile water / bacteriostatic water |
2.1 Amino acid sequence
RPPGFSPFR
3 Research studies (8)
- Bradykinin-induced angioedema in the emergency department
International journal of emergency medicine (2022) · Review - [Drug-induced angioedema : Focus on bradykinin]
Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete (2018) · Review - Intracellular and nuclear bradykinin B2 receptors
European journal of pharmacology (2014) · Review - Immunoassays for des-Arg9-bradykinin
Journal of immunoassay (1993) - Exploring bradykinin: A common mediator in the pathophysiology of sepsis and atherosclerotic cardiovascular disease
Vascular pharmacology (2024) · Review - Bradykinin: Inflammatory Product of the Coagulation System
Clinical reviews in allergy & immunology (2016) · Review - Bradykinin and neuronal injury
Journal of neurotrauma (1992) · Review - Bradykinin receptor expression and bradykinin-mediated sensitization of human sensory neurons
Pain (2024)
4 Safety and risk profile
4.1 Regulatory status
Bradykinin is currently classified as Investigational. It has no approved human indication in the United States; availability elsewhere does not imply demonstrated safety or efficacy.
5 Frequently asked questions
- What is Bradykinin?
- Bradykinin is an endogenous human peptide, also known as Kallidin I, consisting of nine amino acid residues. It is a key component of the kinin-kallikrein system and is involved in various physiological processes within the body.
- How does Bradykinin work?
- Bradykinin's mechanism involves kininogens, which are inhibitors of thiol proteases. Specifically, HMW-kininogen assists in blood coagulation by positioning prekallikrein and factor XI, and both HMW- and LMW-kininogen inhibit platelet aggregation, though LMW-kininogen is not involved in clotting.
- What is Bradykinin studied for?
- Bradykinin is studied for its involvement in conditions such as angioedema, a type of swelling, and its role as a common mediator in the pathophysiology of sepsis and atherosclerotic cardiovascular disease. Research also explores its intracellular and nuclear B2 receptors.
- Is Bradykinin FDA approved?
- No, Bradykinin is currently classified as investigational, meaning it is still undergoing research and has not yet received approval from regulatory bodies like the FDA for therapeutic use.
6 References
- Bradykinin — compound summary PubChem. View source
- Bradykinin — molecule record ChEMBL. View source
- Bradykinin — protein entry UniProt. View source
- Bradykinin — published literature (19,333 records) PubMed. View source
Related compounds
Entries that share a target, a mechanism, or a research area with Bradykinin.
Shares plays and important pharmacology
Thymosin is an endogenous human peptide that plays a role in cytoskeleton organization by binding to and sequestering actin monomers, thereby inhibiting actin polymerization.
Shares coagulation and factor pharmacology
Nonacog Beta Pegol is a coagulation factor IX exogenous protein approved for the treatment of Hemophilia B.
Shares involved and blood pharmacology
Vasoactive Intestinal Peptide (VIP) is a neuropeptide that activates VIP receptor 1 (VPR1) and VIP receptor 2 (VPR2), which are G protein-coupled receptors.
Also recovery
A single amino acid substitution turns GLP-2 from a 7-minute hormone into a drug that regrows intestinal villi. The only approved peptide that makes the gut physically bigger.
Shares position and contrast pharmacology
A six-residue mimic of the SNAP-25 N-terminus, designed to interfere with the same vesicle-fusion machinery botulinum toxin cleaves. The mechanism is real; the question is whether enough of it reaches the muscle.
Also recovery
Three amino acids clipped from the tail of α-MSH — small enough to ride the PepT1 transporter directly into intestinal cells, where it shuts down NF-κB signalling.